Rapidly progressing gene therapy development could push more biotechs to invest in their own manufacturing capabilities over outsourcing to contract services companies. “Greater competition for existing manufacturing capacity likely will result in higher costs or scarcer supplies for customers, and companies may need to make investments into manufacturing technologies – or purchases of companies for their manufacturing expertise – to ensure they are able to compete for gain an edge over other players,” according to a recent PwC report on gene therapy.  Executives at gene therapy biotechs BioMarin Pharmaceutical, MeiraGTx and Audentes Therapeutics voiced similar concerns at a recent gene therapy conference. Learn More